ALKS
Price
$31.00
Change
-$0.54 (-1.71%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
4.55B
47 days until earnings call
DVAX
Price
$9.95
Change
+$0.06 (+0.61%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
1.62B
55 days until earnings call
Interact to see
Advertisement

ALKS vs DVAX

Header iconALKS vs DVAX Comparison
Open Charts ALKS vs DVAXBanner chart's image
Alkermes
Price$31.00
Change-$0.54 (-1.71%)
Volume$27.76K
Capitalization4.55B
Dynavax Technologies
Price$9.95
Change+$0.06 (+0.61%)
Volume$21.14K
Capitalization1.62B
ALKS vs DVAX Comparison Chart
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. DVAX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Buy and DVAX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ALKS: $31.00 vs. DVAX: $9.95)
Brand notoriety: ALKS and DVAX are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 59% vs. DVAX: 51%
Market capitalization -- ALKS: $4.55B vs. DVAX: $1.62B
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. DVAX’s [@Pharmaceuticals: Other] market capitalization is $1.62B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 2 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 2 green, 3 red.
  • DVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 5 TA indicator(s) are bullish while DVAX’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 5 bullish, 4 bearish.
  • DVAX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ALKS and DVAX are a good buy in the short-term.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а +2.46% price change this week, while DVAX (@Pharmaceuticals: Other) price change was +1.95% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.45%. For the same industry, the average monthly price growth was +14.82%, and the average quarterly price growth was +63.61%.

Reported Earning Dates

ALKS is expected to report earnings on Jul 23, 2025.

DVAX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.45% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than DVAX($1.62B). DVAX has higher P/E ratio than ALKS: DVAX (31.63) vs ALKS (8.90). ALKS YTD gains are higher at: 7.771 vs. DVAX (-22.083). ALKS has higher annual earnings (EBITDA): 519M vs. DVAX (9.67M). ALKS (773M) and DVAX (742M) have equal amount of cash in the bank . DVAX has less debt than ALKS: DVAX (257M) vs ALKS (372M). ALKS has higher revenues than DVAX: ALKS (1.66B) vs DVAX (232M).
ALKSDVAXALKS / DVAX
Capitalization4.55B1.62B281%
EBITDA519M9.67M5,369%
Gain YTD7.771-22.083-35%
P/E Ratio8.9031.6328%
Revenue1.66B232M717%
Total Cash773M742M104%
Total Debt372M257M145%
FUNDAMENTALS RATINGS
ALKS vs DVAX: Fundamental Ratings
ALKS
DVAX
OUTLOOK RATING
1..100
205
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
69
Overvalued
PROFIT vs RISK RATING
1..100
2165
SMR RATING
1..100
3891
PRICE GROWTH RATING
1..100
5686
P/E GROWTH RATING
1..100
898
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (69) in the Biotechnology industry is in the same range as ALKS (99). This means that DVAX’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (21) in the Biotechnology industry is somewhat better than the same rating for DVAX (65). This means that ALKS’s stock grew somewhat faster than DVAX’s over the last 12 months.

ALKS's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for DVAX (91). This means that ALKS’s stock grew somewhat faster than DVAX’s over the last 12 months.

ALKS's Price Growth Rating (56) in the Biotechnology industry is in the same range as DVAX (86). This means that ALKS’s stock grew similarly to DVAX’s over the last 12 months.

ALKS's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for DVAX (98). This means that ALKS’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSDVAX
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 15 days ago
63%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCRCX14.150.01
+0.07%
NYLI CBRE Global Infrastructure Class C
MCEIX13.77N/A
N/A
Martin Currie Emerging Markets I
TRRPX18.00N/A
N/A
Nuveen Real Estate Sec Sel Premier
IAFLX18.68N/A
N/A
F/m Investments Large Cap Focused Inst
TRZSX14.56N/A
N/A
T. Rowe Price Overseas Stock Z